From Lab to Patient: The Journey of a Breakthrough Cancer Drug
The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development.
Availability of Publicly Funded Ibrutinib + Venetoclax for CLL Treatment in Canada
There is some good news to share on the treatment front! Since spring 2025, six provinces in Canada have made publicly funded Ibrutinib + Venetoclax (I+V) combination therapy available for previously untreated CLL patients.
Understanding Communication Styles: Have Better Conversations with Your Doctor
Understanding your preferred communication style can significantly enhance your relationship with your healthcare team and empower you to make informed decisions about your health.